Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00461890
Status:
TERMINATED
Last Update Posted:
2011-10-24
First Post:
2007-04-13
Brief Title:
Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs in Specialized Chemical Dependence Treatment A Pilot Trial
Sponsor:
State University of New York - Upstate Medical University
Organization:
State University of New York - Upstate Medical University
Study Overview
Official Title:
Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs in Specialized Chemical Dependence Treatment A Pilot Trial
Status:
TERMINATED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of the proposed project is to improve the primary care treatment of veterans with alcohol dependence Alcohol dependence is a common behavioral health problem among veterans treated in VA primary care clinics However assessment and treatment of alcohol dependence in primary care remains problematic Assessment of veterans with positive alcohol use screens may not always be completed and referrals to specialty care may not always be made Moreover the use of medications for alcohol dependence among veterans is rare despite VA treatment guidelines that recommend such use Finally when medications are prescribed patients may have difficulties with adherence
The primary aim of this study is to assess the feasibility of long-acting injectable naltrexone provided through primary care LANPC versus long-acting injectable naltrexone in the specialized chemical dependence clinic LANCDC The secondary aim is to obtain preliminary assessments of the relative effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic
The primary aim of this study is to assess the feasibility of long-acting injectable naltrexone provided through primary care LANPC versus long-acting injectable naltrexone in the specialized chemical dependence clinic LANCDC The secondary aim is to obtain preliminary assessments of the relative effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None